The Trump administration has brokered a significant deal with Eli Lilly and Novo Nordisk to lower the cost of weight loss drugs for Medicare beneficiaries. Under the agreement, the list prices for Wegovy and Zepbound will drop to approximately $250 per month, with a $50 copay for patients. In exchange, Medicare plans will be required to cover these GLP-1 treatments for weight loss in high-risk individuals, marking a shift in federal policy regarding obesity medication coverage.